A gene therapy that instructs cells to produce more of an anti-ageing protein called klotho is about to be offered by a US company at overseas clinics to bypass FDA rules
An injectable gene therapy that promises to make people live longer will soon become available in certain nations. This is despite the fact that it hasn’t been tested in rigorous clinical trials and doesn’t have approval from the US Food and Drug Administration (FDA) or other major regulators.
The gene therapy, developed by Minicircle – a company headquartered in Austin, Texas – is designed to make cells produce more of an anti-ageing protein called klotho. To get around the extensive clinical testing required by the FDA to approve a therapeutic product in the US, Minicircle will offer the largely untested gene therapy to those willing to travel to Honduras, the Bahamas or Panama. The company has opened a waitlist on its website and says it will make the treatment available in the next six months.
read the full story: Unapproved gene therapy for boosting longevity is set to go on sale, New Scientist
details